Stock Ratings / Health Care / ANRO / options

CYRX (38) ORIC (39) JBIO (36) AKTS (56) ⌘ Pro Terminal →

Alto Neuroscience Inc. (ANRO) Options Positioning, Max Pain & Unusual Sweeps

$23.47 +0.60% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Alto Neuroscience Inc. (ANRO) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $921.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANRO)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ANRO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ANRO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANRO)

✓Walkthrough of ANRO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANRO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.53%📐 HORIZONTAL RANGE

2026-10-30O $23.21H $23.47L $21.90C $23.47VOL 484.4K

RES: $44.01SUP: $20.81SMA50: $28.27SMA200: $24.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANRO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANRO Butterfly Map → + Track ANRO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANRO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANRO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANRO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANRO)

Health Care Rank #702 of 1016 ⚔️ CYRX vs ANRO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANRO vs. CYRX, ORIC, JBIO, AKTS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alto Neuroscience Inc. (ANRO) ranks #702 by composite RQD confidence (38/100, grade D-) and #374 by equity capitalization ($921.0M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. AKTS currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with ANRO at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANRO ACTIVE Alto Neuroscience Inc.	D-	38/100	—	—	-35.0%	+0.60%	$921.0M	Benchmark Subject
CYRX CryoPort Inc.	D-	38/100	11.8x	47.1%	-11.5%	-1.88%	$926.4M	/cyrx-vs-anro →
ORIC Oric Pharmaceuticals Inc.	D-	39/100	—	—	-33.4%	-3.33%	$931.8M	/oric-vs-anro →
JBIO Jade Biosciences Inc.	D-	36/100	—	—	-35.0%	-2.40%	$905.6M	/jbio-vs-anro →
AKTS Aktis Oncology Inc.	D+	56/100	—	—	—	+0.18%	$937.2M	/akts-vs-anro →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001999480

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alto Neuroscience Inc. (ANRO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$63.2M, operating cash flow of -$51.8M, and free cash flow of -$51.8M (-4.6% YoY). On the balance sheet, ANRO closed FY2025 with $184.7M in total assets against $16.2M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$63.2M	-$51.8M	-$51.8M	$184.7M	$16.2M
FY2024 (FY)	2024-12-31	$0	-$61.4M	-$47.4M	-$49.5M	$177.5M	$10.3M
FY2023 (FY)	2023-12-31	$0	-$36.3M	-$33.4M	-$33.4M	—	—

3. ANRO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Alto Neuroscience Inc. (NYSE: ANRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $23.47 (+0.60% 1D, market cap $921.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ANRO ranks #702 in composite RQD confidence.

How does ANRO compare to CYRX and ORIC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANRO carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CYRX (CryoPort Inc.) holds a D- grade (38/100 RQD, P/E 11.8x, ROIC -11.5%, cap $926.4M) and ORIC (Oric Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANRO?

Per ANRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001999480), Alto Neuroscience Inc. generated $0 in revenue, -$63.2M in net income, and -$51.8M in free cash flow against $184.7M in total assets and $16.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANRO trading relative to its 50-day, 200-day, and 52-week technical levels?

ANRO last traded at $23.47 (+0.60% on volume of 388,847 shares), positioning the stock -16.98% below its 50-day simple moving average ($28.27) and -3.26% below its 200-day simple moving average ($24.26). Across its 52-week range of $10.20 to $37.48, ANRO sits at the 48.6% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($20.54 to $26.40).

ANRO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ANRO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ANRO.

Direct Sub-Reports: ANRO RQD Cockpit ANRO 12M Forecast ANRO Earnings & Move ANRO Dividends & DRIP ANRO Insiders & 13F ANRO Whale Options ANRO Profit Sankey ANRO News & Why